Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Institut Jules Bordet, Dana-Farber Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Yale University, OU Health Stephenson Cancer Center, Universitair Ziekenhuis Leuven, University of Colorado Cancer Center, University of Iowa Holden Comprehensive Cancer Center, University of California San Diego, Stanford University, The Ohio State University Wexner Medical Center, Duke Medical Center, Duke Cancer Institute, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947249374